Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

[1]  Amine Kamen,et al.  Development and optimization of an adenovirus production process , 2004, The journal of gene medicine.

[2]  Christian M. Metallo,et al.  Large-scale propagation of a replication-defective adenovirus vector in stirred-tank bioreactor PER.C6 cell culture under sparging conditions. , 2003, Biotechnology and bioengineering.

[3]  A. Smith,et al.  Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines , 2003, Gene Therapy.

[4]  M. Hilleman,et al.  Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. , 2002, Vaccine.

[5]  R. Webster,et al.  Eight-plasmid system for rapid generation of influenza virus vaccines. , 2002, Vaccine.

[6]  J. Files,et al.  A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles. , 2002, Human gene therapy.

[7]  G. Schild,et al.  Preparation of vaccines against H5N1 influenza. , 2002, Vaccine.

[8]  D. Tang,et al.  Induction of protective immunity by topic application of a recombinant adenovirus expressing rabies virus glycoprotein. , 2002, Veterinary microbiology.

[9]  Mark Wolff,et al.  Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. , 2002, Vaccine.

[10]  C. Elmets,et al.  Protection against Tetanus by Needle-Free Inoculation of Adenovirus-Vectored Nasal and Epicutaneous Vaccines , 2001, Journal of Virology.

[11]  C. Elmets,et al.  AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination. , 2001, BioTechniques.

[12]  Lihan K. Yan,et al.  Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. , 2000, The Journal of infectious diseases.

[13]  Potter,et al.  Intranasal immunization with inactivated influenza vaccine. , 1999, Pharmaceutical science & technology today.

[14]  Tokiko Watanabe,et al.  Generation of influenza A viruses entirely from cloned cDNAs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  B. Ramsey,et al.  Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. , 1998, Pediatrics.

[16]  D. Tang,et al.  Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells. , 1997, Human gene therapy.

[17]  K. Mozdzanowska,et al.  A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro , 1997, Journal of virology.

[18]  B. Sugarman,et al.  Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. , 1997, Human gene therapy.

[19]  B. Trapnell,et al.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy , 1996, Journal of virology.

[20]  Z. Xiang,et al.  A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. , 1996, Virology.

[21]  J. Ryerse,et al.  The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells , 1996, Journal of virology.

[22]  C. Naeve,et al.  Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses. , 1995, Virology.

[23]  D. Carbone,et al.  Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. , 1994, Cancer gene therapy.

[24]  D. Fuller,et al.  Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. , 1993, DNA and cell biology.

[25]  F. Graham,et al.  Packaging capacity and stability of human adenovirus type 5 vectors , 1993, Journal of virology.

[26]  E. Swierkosz,et al.  Sequence of an influenza virus hemagglutinin determined directly from a clinical sample. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Fields,et al.  Nucleotide sequence of the haemagglutinin gene of a human influenza virus H1 subtype , 1981, Nature.